Teva's Allergan Generics Buy Progressing, Though Timeline Might Slip
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries Ltd. assured investors that its $40.5bn deal to buy Allergan PLC's generic drug business is progressing as expected during the company's fourth quarter sales and earnings call on Feb. 11, although CEO-Global Generic Medicines Sigurdur Olafsson said the timeline of the closing could slip from the first quarter into the first part of the second.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.